Lose dose genistein inhibits glucocorticoid receptor and ischemic brain injury in female rats

Rengfei Shi, Shunli Wang, Xiang Qi, Si Chen, Peijie Chen, Quanguang Zhang

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Although acute bolus of genistein treatment has been shown to protect against neuronal damage in experimental brain injury animal models, chronic continuous low dose treatment of genistein on ischemic brain injury has not been well elucidated. In the present study, female rats were received either pure genistein (0.1 mg/kg/day via osmotic minipumps) or placebo at the time of ovariectomy, and transient forebrain ischemia was induced 7 days later. Results demonstrated that genistein treatment for 14 days significantly improved ischemic neuronal survival in hippocampal CA1 region of ovariectomized rats. Glucocorticoid receptor (GR) is a member of the adrenal steroid hormone receptor, which is highly expressed in the rat hippocampus. Activation of the GR plays a critical role in the neuronal stress responses, including ischemic brain damage. This study therefore examined the potential mechanisms by which genistein regulates GR signaling, including the protein distribution and receptor activation in hippocampus following ischemic reperfusion (I/R). Results showed that GR expression in the ovariectomized rats was excessively increased both in neurons (I/R 6 h) and activated microglial cells (I/R 7 d) in hippocampal CA1 region. Genistein treatment significantly attenuated GR induction and the enhanced GR nuclear translocation and DNA-binding capacity. The effects of genistein on the GR levels was accompanied with decreased blood plasma levels of corticosterone (primary glucocorticoid in rodents) and coupled to an E3 ubiquitin ligase Mdm2 targeted proteasomal degradation of GR, because genistein treatment could enhance the GR-Mdm2 interaction and the ubiquitination level of GR protein. In addition, our results indicated that genistein markedly prevented the excessive activation of microglia in CA1 sector. These results demonstrate the neuroprotective action of chronic low dose genistein replacement against ischemic brain damage, and a potential mechanism associated with the inhibition of both neuronal and microglial GR signaling following ischemic stress.

Original languageEnglish (US)
Pages (from-to)14-22
Number of pages9
JournalNeurochemistry International
Volume65
Issue number1
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Genistein
Glucocorticoid Receptors
Brain Injuries
Reperfusion
Hippocampal CA1 Region
Hippocampus
Therapeutics
Ubiquitin-Protein Ligases
Steroid Receptors
Ubiquitination
Brain
Microglia
Ovariectomy
Corticosterone
Prosencephalon
Glucocorticoids
Rodentia
Proteins
Ischemia
Animal Models

Keywords

  • Brain injury
  • Genistein replacement
  • Glucocorticoid receptor
  • Hippocampus
  • Microglia
  • Osmotic pump
  • Transient forebrain ischemia

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Cell Biology

Cite this

Lose dose genistein inhibits glucocorticoid receptor and ischemic brain injury in female rats. / Shi, Rengfei; Wang, Shunli; Qi, Xiang; Chen, Si; Chen, Peijie; Zhang, Quanguang.

In: Neurochemistry International, Vol. 65, No. 1, 01.01.2014, p. 14-22.

Research output: Contribution to journalArticle

Shi, Rengfei ; Wang, Shunli ; Qi, Xiang ; Chen, Si ; Chen, Peijie ; Zhang, Quanguang. / Lose dose genistein inhibits glucocorticoid receptor and ischemic brain injury in female rats. In: Neurochemistry International. 2014 ; Vol. 65, No. 1. pp. 14-22.
@article{ee78c02b534440b1866a5e486c798c94,
title = "Lose dose genistein inhibits glucocorticoid receptor and ischemic brain injury in female rats",
abstract = "Although acute bolus of genistein treatment has been shown to protect against neuronal damage in experimental brain injury animal models, chronic continuous low dose treatment of genistein on ischemic brain injury has not been well elucidated. In the present study, female rats were received either pure genistein (0.1 mg/kg/day via osmotic minipumps) or placebo at the time of ovariectomy, and transient forebrain ischemia was induced 7 days later. Results demonstrated that genistein treatment for 14 days significantly improved ischemic neuronal survival in hippocampal CA1 region of ovariectomized rats. Glucocorticoid receptor (GR) is a member of the adrenal steroid hormone receptor, which is highly expressed in the rat hippocampus. Activation of the GR plays a critical role in the neuronal stress responses, including ischemic brain damage. This study therefore examined the potential mechanisms by which genistein regulates GR signaling, including the protein distribution and receptor activation in hippocampus following ischemic reperfusion (I/R). Results showed that GR expression in the ovariectomized rats was excessively increased both in neurons (I/R 6 h) and activated microglial cells (I/R 7 d) in hippocampal CA1 region. Genistein treatment significantly attenuated GR induction and the enhanced GR nuclear translocation and DNA-binding capacity. The effects of genistein on the GR levels was accompanied with decreased blood plasma levels of corticosterone (primary glucocorticoid in rodents) and coupled to an E3 ubiquitin ligase Mdm2 targeted proteasomal degradation of GR, because genistein treatment could enhance the GR-Mdm2 interaction and the ubiquitination level of GR protein. In addition, our results indicated that genistein markedly prevented the excessive activation of microglia in CA1 sector. These results demonstrate the neuroprotective action of chronic low dose genistein replacement against ischemic brain damage, and a potential mechanism associated with the inhibition of both neuronal and microglial GR signaling following ischemic stress.",
keywords = "Brain injury, Genistein replacement, Glucocorticoid receptor, Hippocampus, Microglia, Osmotic pump, Transient forebrain ischemia",
author = "Rengfei Shi and Shunli Wang and Xiang Qi and Si Chen and Peijie Chen and Quanguang Zhang",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.neuint.2013.12.002",
language = "English (US)",
volume = "65",
pages = "14--22",
journal = "Neurochemistry International",
issn = "0197-0186",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Lose dose genistein inhibits glucocorticoid receptor and ischemic brain injury in female rats

AU - Shi, Rengfei

AU - Wang, Shunli

AU - Qi, Xiang

AU - Chen, Si

AU - Chen, Peijie

AU - Zhang, Quanguang

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Although acute bolus of genistein treatment has been shown to protect against neuronal damage in experimental brain injury animal models, chronic continuous low dose treatment of genistein on ischemic brain injury has not been well elucidated. In the present study, female rats were received either pure genistein (0.1 mg/kg/day via osmotic minipumps) or placebo at the time of ovariectomy, and transient forebrain ischemia was induced 7 days later. Results demonstrated that genistein treatment for 14 days significantly improved ischemic neuronal survival in hippocampal CA1 region of ovariectomized rats. Glucocorticoid receptor (GR) is a member of the adrenal steroid hormone receptor, which is highly expressed in the rat hippocampus. Activation of the GR plays a critical role in the neuronal stress responses, including ischemic brain damage. This study therefore examined the potential mechanisms by which genistein regulates GR signaling, including the protein distribution and receptor activation in hippocampus following ischemic reperfusion (I/R). Results showed that GR expression in the ovariectomized rats was excessively increased both in neurons (I/R 6 h) and activated microglial cells (I/R 7 d) in hippocampal CA1 region. Genistein treatment significantly attenuated GR induction and the enhanced GR nuclear translocation and DNA-binding capacity. The effects of genistein on the GR levels was accompanied with decreased blood plasma levels of corticosterone (primary glucocorticoid in rodents) and coupled to an E3 ubiquitin ligase Mdm2 targeted proteasomal degradation of GR, because genistein treatment could enhance the GR-Mdm2 interaction and the ubiquitination level of GR protein. In addition, our results indicated that genistein markedly prevented the excessive activation of microglia in CA1 sector. These results demonstrate the neuroprotective action of chronic low dose genistein replacement against ischemic brain damage, and a potential mechanism associated with the inhibition of both neuronal and microglial GR signaling following ischemic stress.

AB - Although acute bolus of genistein treatment has been shown to protect against neuronal damage in experimental brain injury animal models, chronic continuous low dose treatment of genistein on ischemic brain injury has not been well elucidated. In the present study, female rats were received either pure genistein (0.1 mg/kg/day via osmotic minipumps) or placebo at the time of ovariectomy, and transient forebrain ischemia was induced 7 days later. Results demonstrated that genistein treatment for 14 days significantly improved ischemic neuronal survival in hippocampal CA1 region of ovariectomized rats. Glucocorticoid receptor (GR) is a member of the adrenal steroid hormone receptor, which is highly expressed in the rat hippocampus. Activation of the GR plays a critical role in the neuronal stress responses, including ischemic brain damage. This study therefore examined the potential mechanisms by which genistein regulates GR signaling, including the protein distribution and receptor activation in hippocampus following ischemic reperfusion (I/R). Results showed that GR expression in the ovariectomized rats was excessively increased both in neurons (I/R 6 h) and activated microglial cells (I/R 7 d) in hippocampal CA1 region. Genistein treatment significantly attenuated GR induction and the enhanced GR nuclear translocation and DNA-binding capacity. The effects of genistein on the GR levels was accompanied with decreased blood plasma levels of corticosterone (primary glucocorticoid in rodents) and coupled to an E3 ubiquitin ligase Mdm2 targeted proteasomal degradation of GR, because genistein treatment could enhance the GR-Mdm2 interaction and the ubiquitination level of GR protein. In addition, our results indicated that genistein markedly prevented the excessive activation of microglia in CA1 sector. These results demonstrate the neuroprotective action of chronic low dose genistein replacement against ischemic brain damage, and a potential mechanism associated with the inhibition of both neuronal and microglial GR signaling following ischemic stress.

KW - Brain injury

KW - Genistein replacement

KW - Glucocorticoid receptor

KW - Hippocampus

KW - Microglia

KW - Osmotic pump

KW - Transient forebrain ischemia

UR - http://www.scopus.com/inward/record.url?scp=84891550426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891550426&partnerID=8YFLogxK

U2 - 10.1016/j.neuint.2013.12.002

DO - 10.1016/j.neuint.2013.12.002

M3 - Article

VL - 65

SP - 14

EP - 22

JO - Neurochemistry International

JF - Neurochemistry International

SN - 0197-0186

IS - 1

ER -